- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00825305
Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)
December 7, 2011 updated by: Novartis Vaccines
A Phase III, Single Center, Randomized, Open-label Study, Comparing PCECV Administered in the Abbreviated Zagreb Regimen (2-1-1) to the Conventional Essen Regimen (1-1-1-1-1) in Healthy Volunteers in China
This study investigates the safety and immunogenicity (non-inferiority) of a Purified Chick Embryo Cell Vaccine (PCECV) administered in two different schedules (conventional versus abbreviated schedule) in healthy adults 18 to 50 years of age in China
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
825
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hebei
-
Jizhou City, Hebei, China, 053200
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects 18-50 years of age who:
- are in good health at the time of entry into the study as determined by medical history, physical examination and clinical judgment of the investigator;
- volunteer for the simulated post-exposure vaccination courses and blood draws;
- have given a written informed consent; informed consent must be obtained for all the subjects before enrolment in the study;
- are available for all the visits scheduled in the study.
Exclusion Criteria:
- Subjects with the below criteria were excluded:
- pregnancy or unwillingness to practice acceptable contraception during participation in the study;
- a history of rabies immunization;
- a significant acute or chronic infectious disease that may impact the subject's safety and /or immunogenicity in the Investigators opinion at the time of enrolment;
- fever ≥ 38.0°C (axillary) or/and significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrolment;
- treatment with corticosteroids, immunosuppressive or antimalaria drugs during the two month period before enrolment;
- administration of any vaccine within the past 14 days before enrolment;
- known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;
- history of allergy to egg protein;
- known hypersensitivity to neomycin, tetracycline, amphotericin-B, or any other vaccine component;
- treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months;
- mental condition rendering the subject unable to understand the nature, scope and consequences of the study;
- participation in any other investigational trial within the past 3 months before enrolment;
- planned surgery during the study period;
- intention to leave the area of the study site before the end of study period;
- any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objective.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zagreb (2-1-1)
Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
|
Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
Other Names:
|
Active Comparator: Essen (1-1-1-1-1)
Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.
|
Subjects received the standard Essen regimen.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rabies Virus Neutralizing Antibody Concentrations on Day 14.
Time Frame: 14 days
|
Rabies virus neutralizing antibody concentrations of the abbreviated Zagreb regimen compared with the conventional Essen regimen.
Results are presented on log2 scale.
For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.
|
14 days
|
Number of Participants Who Reported a Local or Systemic Reaction After Any Vaccination
Time Frame: 7 days after each vaccination
|
Specified local and systemic reactions were solicited for 7 days after each vaccination.
Number of participants were calculated who reported a local or systemic reaction after any of the vaccinations.
|
7 days after each vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rabies Virus Neutralizing Antibody Concentrations on Day 7 and Day 42.
Time Frame: 7 days and 42 days
|
Rabies virus neutralizing antibody concentrations the abbreviated Zagreb regimen compared with the conventional Essen regimen.
Results are presented on log2 scale.
For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.
|
7 days and 42 days
|
Percentages of Participants With Seroconversion (Rabies Virus Neutralizing Antibody Concentrations Equal and Above 0.5 IU/ml) on Days 7, 14 and 42.
Time Frame: 7 days, 14 days and 42 days
|
Percentages of participants with seroconversion (defined as rabies virus neutralizing antibody concentrations equal and above 0.5 IU/ml) on days 7, 14 and 42.
|
7 days, 14 days and 42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
January 1, 2009
Study Registration Dates
First Submitted
January 19, 2009
First Submitted That Met QC Criteria
January 20, 2009
First Posted (Estimate)
January 21, 2009
Study Record Updates
Last Update Posted (Estimate)
December 13, 2011
Last Update Submitted That Met QC Criteria
December 7, 2011
Last Verified
December 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M49P8
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rabies
-
The Methodist Hospital Research InstituteGrifols Biologicals, LLCCompletedRabies | Rabies Human | Rabies Virus InfectionUnited States
-
The Methodist Hospital Research InstituteGrifols Biologicals, LLCRecruitingRabies | Rabies Human | Pediatrics | Rabies Virus InfectionUnited States
-
Centers for Disease Control and PreventionCompletedRabies Prevention | Rabies ExposureUnited States
-
Changchun Zhuoyi Biological Co., LtdEnrolling by invitation
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruiting
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Synermore Biologics Co., Ltd.inVentiv Health ClinicalCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Provincial Public Health Office, PhetchabunCompleted
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Sponsor GmbHCompletedRabies Vaccine Adverse ReactionChina
Clinical Trials on Abbreviated Zagreb 2-1-1 schedule
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Hunan Provincial Center for... and other collaboratorsNot yet recruiting
-
China National Biotec Group Company LimitedWuhan Institute of Biological Products Co., Ltd; Hunan Provincial Center for... and other collaboratorsNot yet recruiting
-
Hanmi Pharmaceutical Company LimitedCompletedHypertensionKorea, Republic of
-
Chulalongkorn UniversityCompletedAllergic RhinitisThailand
-
Janssen Research & Development, LLCCompletedRelapsed or Refractory Hodgkin LymphomaFrance, Germany
-
Orasis Pharmaceuticals Ltd.Completed
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Recruiting
-
Hanmi Pharmaceutical Company LimitedNot yet recruiting
-
Oticon MedicalCompleted